RT Journal Article
SR Electronic
T1 Fine-mapping across diverse ancestries drives the discovery of putative causal variants underlying human complex traits and diseases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.07.23284293
DO 10.1101/2023.01.07.23284293
A1 Yuan, Kai
A1 Longchamps, Ryan J.
A1 Pardiñas, Antonio F.
A1 Yu, Mingrui
A1 Chen, Tzu-Ting
A1 Lin, Shu-Chin
A1 Chen, Yu
A1 Lam, Max
A1 Liu, Ruize
A1 Xia, Yan
A1 Guo, Zhenglin
A1 Shi, Wenzhao
A1 Shen, Chengguo
A1 ,
A1 Daly, Mark J.
A1 Neale, Benjamin M.
A1 Feng, Yen-Chen A.
A1 Lin, Yen-Feng
A1 Chen, Chia-Yen
A1 O’Donovan, Michael
A1 Ge, Tian
A1 Huang, Hailiang
YR 2023
UL http://medrxiv.org/content/early/2023/07/09/2023.01.07.23284293.abstract
AB Genome-wide association studies (GWAS) of human complex traits or diseases often implicate genetic loci that span hundreds or thousands of genetic variants, many of which have similar statistical significance. While statistical fine-mapping in individuals of European ancestries has made important discoveries, cross-population fine-mapping has the potential to improve power and resolution by capitalizing on the genomic diversity across ancestries. Here we present SuSiEx, an accurate and computationally efficient method for cross-population fine-mapping, which builds on the single-population fine-mapping framework, Sum of Single Effects (SuSiE). SuSiEx integrates data from an arbitrary number of ancestries, explicitly models population-specific allele frequencies and LD patterns, accounts for multiple causal variants in a genomic region, and can be applied to GWAS summary statistics. We comprehensively evaluated SuSiEx using simulations, a range of quantitative traits measured in both UK Biobank and Taiwan Biobank, and schizophrenia GWAS across East Asian and European ancestries. In all evaluations, SuSiEx fine-mapped more association signals, produced smaller credible sets and higher posterior inclusion probability (PIP) for putative causal variants, and captured population-specific causal variants.Competing Interest StatementW.S. and C.S. are employees of Digital Health China Technologies Corp. Ltd.. M.J.D. is a founder of Maze Therapeutics. C.Y.C. is an employee of Biogen. H.H. received consultancy fees from Ono Pharmaceutical and honorarium from Xian Janssen Pharmaceutical.Funding StatementH.H. acknowledges supports from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) K01DK114379 and R01DK129364, National Institute of Mental Health (NIMH) U01MH109539 and R01MH130675, Brain and Behavior Research Foundation Young Investigator Grant (28450), the Zhengxu and Ying He Foundation, and the Stanley Center for Psychiatric Research. T.G. is supported by National Institute on Aging (NIA) R00AG054573 and National Human Genome Research Institute (NHGRI) R56HG012354. Y.F.L. is supported by the National Health Research Institutes (NP-109-PP-09), and the Ministry of Science and Technology (109-2314-B-400-017) of Taiwan. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Collection of the UKBB data was approved by the Research Ethics Committee of the UKBB. UKBB individual-level data used in the present work were obtained under application no. 32568. Collection of the TWB data was approved by the Ethics and Governance Council (EGC) of TWB and the Department of Health and Welfare, Taiwan (Wei-Shu-I-Tzu no.1010267471). TWB obtained informed consent from all participants for research use of the collected data. Access to, and use of, TWB data in the present work was approved by the EGC of TWB (approval number: TWBR10907-05) and the Institutional Review Board of National Health Research Institutes, Taiwan (approval number: EC1090402-E).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPublicly available data are available from the following sites: 1KG Phase 3 reference panels: https://mathgen.stats.ox.ac.uk/impute/1000GP_Phase3.html. Genetic map for each subpopulation: https://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20130507_omni_recombination_rates. Individual-level genotypes for UKBB samples were obtained under application 32568. UKBB European and African GWAS summary statistics were obtained from the PanUKBB Project. https://pan.ukbb.broadinstitute.org/downloads. The GWAS summary statistics and in-sample LD of European and Asian for the schizophrenia analysis were obtained from the Schizophrenia Working Group of the Psychiatric Genomic Consortium (PGC). https://figshare.com/articles/dataset/scz2022/19426775. Taiwan Biobank data used in this study contain protected health information and are thus under controlled access. Application to access such data can be made to the Taiwan Biobank. https://taiwanview.twbiobank.org.tw/data_appl.